Safety of Hyaluronic Acid Fillers During Breastfeeding
Introduction to Hyaluronic Acid Fillers and Breastfeeding
- Most medications that breastfeeding women take are compatible with breastfeeding, with only a limited number of agents being contraindicated, according to the American Academy of Pediatrics 1, 2
- Hyaluronic acid fillers are not specifically mentioned in guidelines on medications during breastfeeding, suggesting they are not considered high-risk, as per the American Academy of Pediatrics 1, 2, 3
Decision-Making for Breastfeeding Women Considering Hyaluronic Acid Fillers
- When considering the necessity of the procedure, it is recommended to assess if the procedure can be delayed until after breastfeeding is complete, weighing benefits against potential risks, as suggested by the American Society of Anesthesiologists 1, 4
- For pain management, ibuprofen and paracetamol are considered safe during breastfeeding, according to the American College of Obstetricians and Gynecologists 10
- If sedation is required, midazolam is preferred over diazepam as it has lower transfer to breast milk, as recommended by the American Society of Anesthesiologists 4, 7, 8, 9
Post-Procedure Considerations
- No specific waiting period before breastfeeding is required after HA filler procedures, as stated by the American Academy of Pediatrics 1
- Monitor for any unusual reactions in both mother and infant, as advised by the American Society of Anesthesiologists 4, 8
Benefits of Breastfeeding and Cosmetic Treatments
- The benefits of breastfeeding are significant for both mother and infant, including protection against infectious diseases, reduced risk of certain cancers, and other health benefits, as highlighted by the European League Against Rheumatism 5, 6
- Given these benefits, women should not be discouraged from breastfeeding while taking compatible medications, as recommended by the European League Against Rheumatism 5, 6
- The choice of cosmetic treatments during breastfeeding should be a shared decision-making process between healthcare providers and the patient, as suggested by the European League Against Rheumatism 5, 6